Mycological cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes mycological cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with terbinafine (moderate certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · participants with confirmed toenail onychomycosis
Azole showed no clear difference in recurrence rate compared with terbinafine (low certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Terbinafine leads to higher clinical cure compared with placebo (high certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Terbinafine leads to higher mycological cure compared with placebo (high certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Terbinafine showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
Terbinafine may leads to lower recurrence rate compared with placebo (low certainty).
1 finding from 1 review
PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis
1 finding from 1 review
Quality of life (QoL) ‐ not measured · psoriasis
1 finding from 1 review
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).
1 finding from 1 review
PASI 50 · psoriasis
It is very uncertain whether FAE changes PASI 50 compared with MTX (very low certainty).
1 finding from 1 review
Percentage of participants reaching PASI 75 · psoriasis
It is very uncertain whether FAE changes PASI 75 compared with MTX (very low certainty).
1 finding from 1 review
PASI 90 · psoriasis
It is very uncertain whether FAE changes PASI 90 compared with MTX (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
1 finding from 1 review
QoL · psoriasis
1 finding from 1 review
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
FAE probably leads to higher common nuisance AEs (not leading to treatment discontinuation) compared with placebo (moderate certainty).
1 finding from 1 review